AUBAGNE, France & GOETTINGEN, Germany & MONTREAL--(BUSINESS WIRE)--Sartorius Stedim Biotech (Paris:DIM) and ProMetic Life Sciences Inc. (“ProMetic”) (TSX:PLI) announced today the second successful technology transfer deal resulting from their collaboration entered into in 2006. The collaboration positions Sartorius Stedim Biotech as the preferred supplier and technology provider of filtration equipment and consumables to plasma fractionators that have in-licensed ProMetic’s proprietary manufacturing process.
